A Multidisciplinary Approach to Standardizing Processes for Blinatumomab Administration.
Blinatumomab (Blincyto®) has received accelerated approval for treatment of relapsed or refractory acute lymphoblastic leukemia. This article describes the authors' experience with a multidisciplinary collaboration among nursing, pharmacy, prescribers, and support staff, which has proven to be key for safe administration. The approach can be applied to other institutions planning to use blinatumomab.
Hackensack University Medical Center.
Samantha
S
DePadova
Rutgers State University.
Christina
C
Howlett
Hackensack University Medical Center.
Kimberly
K
Rivera
D000328:Adult; D000368:Aged; D018033:Antibodies, Bispecific / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000592:standards*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D033183:Interdisciplinary Communication; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
D018033:Antibodies, Bispecific; D000970:Antineoplastic Agents; C510808:blinatumomab
acute lymphoblastic leukemia; blinatumomab; education; multidiscipinary collaboration